In H pylori infection, vonoprazan plus high-dose amoxicillin was noninferior to B-quadruple therapy for eradication
- PMID: 37126819
- DOI: 10.7326/J23-0028
In H pylori infection, vonoprazan plus high-dose amoxicillin was noninferior to B-quadruple therapy for eradication
Erratum in
-
Corrections to ACP Journal Club: Errors in Clinical Impact Ratings.Ann Intern Med. 2023 Dec;176(12):JC144. doi: 10.7326/J23-0087. Epub 2023 Oct 3. Ann Intern Med. 2023. PMID: 37782926 No abstract available.
Abstract
Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118:627-634. 36729890.
Conflict of interest statement
Comment on
-
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.Am J Gastroenterol. 2023 Apr 1;118(4):627-634. doi: 10.14309/ajg.0000000000002086. Epub 2022 Dec 2. Am J Gastroenterol. 2023. PMID: 36729890 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical